Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of May 2020, with the report dated May 12, 2020. The filing details the completion of a strategic divestment involving GSK's Consumer Healthcare nutrition products in India, specifically the Horlicks brand.
Key Financial Metrics
- Transaction Proceeds: GSK sold 133,772,044 ordinary shares in Hindustan Unilever Limited (HUL) at a volume-weighted average price of approximately Rs. 1,905 per share.
- Gross Proceeds from Sale: Approximately Rs. 254.8 billion.
- Revised Total Divestment Expectations: Due to HUL share price appreciation, GSK now expects total gross proceeds from the overall divestment (including the April 2020 closing and the pending Bangladesh business sale) to be approximately £3.4 billion.
- Net Proceeds Expectation: Approximately £2.9 billion after hedging costs, taxes, and other expenses.
- Stake Disposal: Following this sale, GSK no longer holds any shares in HUL, having previously acquired a 5.7% stake through the merger of GSK India with HUL.
Material Changes Versus Prior Period
Compared to the original announcement in December 2018, the expected financial outcome of the divestment has improved significantly:
- Gross Proceeds Increase: Revised from an expected £3.1 billion to £3.4 billion.
- Net Proceeds Increase: Revised from an expected £2.4 billion to £2.9 billion.
- Driver of Change: The increase is attributed to the appreciation of HUL's share price since the initial announcement.
Outlook, Risks, and Contingencies
Outlook: The transaction includes proceeds from the closing on April 1, 2020, and expected proceeds from the sale of GSK's Bangladesh business, which is anticipated to close later in 2020.
Risks and Contingencies: GSK includes a cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks and uncertainties. Specific factors cited include those described in the 2019 Annual Report on Form 20-F and the impacts of the COVID-19 pandemic.
Unusual Items: The filing notes that the announcement is not for release in the United States and is restricted to qualified investors in the EEA and UK. The placement agents (HSBC, J.P. Morgan, and Morgan Stanley) may participate on a proprietary basis.
Key Facts for Investor Verification
- Verify the final closing date and actual proceeds from the Bangladesh business sale to confirm the total net proceeds reach the projected £2.9 billion.
- Confirm the final tax and hedging costs incurred to validate the net proceeds calculation.
- Review the 2019 Form 20-F for detailed risk factors referenced in the cautionary statement.
- Monitor the impact of the COVID-19 pandemic on GSK's broader Consumer Healthcare portfolio beyond the divested Indian assets.